
Atuveciclib
CAS No. 1414943-88-6
Atuveciclib ( BAY 1143572 | BAY1143572 )
产品货号. M11720 CAS No. 1414943-88-6
Atuveciclib (BAY-1143572) 是一种有效的、高选择性的、口服生物可利用的 CDK9/P-TEFb 抑制剂,对 CDK9/CyclinT1 的 IC50 为 6 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥2341 | 有现货 |
![]() ![]() |
10MG | ¥3742 | 有现货 |
![]() ![]() |
25MG | ¥7023 | 有现货 |
![]() ![]() |
50MG | ¥9396 | 有现货 |
![]() ![]() |
100MG | ¥12717 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Atuveciclib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Atuveciclib (BAY-1143572) 是一种有效的、高选择性的、口服生物可利用的 CDK9/P-TEFb 抑制剂,对 CDK9/CyclinT1 的 IC50 为 6 nM。
-
产品描述Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6 nM for CDK9/CyclinT1; displays >150-fold selectivity over CDK1/2/3/5/6/7 (IC50>800 nM), also shows submicromolar inhibitory activity against GSK3α (IC50=45 nM), GSK3β (IC50=87?nM); demonstrates antiproliferative activity against HeLa cells (IC50=920 nM) and MOLM‐13 cells (IC50=310 nM); exhibits anticancer activity in human AML models.Blood Cancer Phase 1 Clinical.
-
体外实验Atuveciclib (BAY-1143572) inhibits the proliferation of 7 MLL-rearrangements positive and negative AML cell lines with a median IC50 of 385 nM (range 230-1100 nM) and induces apoptosis. Atuveciclib (BAY-1143572) has potent and highly selective PTEFb-kinase inhibitory activity in the low nanomolar range against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs. Atuveciclib (BAY-1143572) shows a favorable selectivity against a panel of non-CDK kinases. It shows broad antiproliferative activity against a panel of tumor cell lines with sub-micromolar IC50 values. The concentration-dependent inhibition of the phosphorylation of the RNA polymerase II and downstream reduction of MYC mRNA and protein levels is observed.
-
体内实验Atuveciclib (BAY-1143572) exhibits single agent efficacy at tolerated doses in 4 out of 5 AML xenograft tumor models in mice and in 2 out of 2 AML xenograft tumor models in rats upon once daily oral administration. Partial or even complete remissions could be achieved in several models.The inhibition of MYC mRNA is also observed in blood cells of Atuveciclib (BAY-1143572)-treated rats indicating the potential clinical utility of MYC in blood cells as a pharmacodynamic marker in clinical development. The in vivo efficacy of Atuveciclib (BAY-1143572) is significantly enhanced in combination with several chemotherapeutics in different solid tumor models.
-
同义词BAY 1143572 | BAY1143572
-
通路Cell Cycle/DNA Damage
-
靶点CDK
-
受体CDK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1414943-88-6
-
分子量387.433
-
分子式C18H18FN5O2S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (258.11 mM)
-
SMILESO=S(C)(CC1=CC=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=C1)=N
-
化学全称(3-((4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino)benzyl)(imino)(methyl)-l6-sulfanone
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Lücking U, et al. ChemMedChem. 2017 Nov 8;12(21):1776-1793.
2. Narita T, et al. Blood. 2017 Aug 31;130(9):1114-1124.
产品手册




关联产品
-
WAY-322243
WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.
-
Atuveciclib
Atuveciclib (BAY-1143572) 是一种有效的、高选择性的、口服生物可利用的 CDK9/P-TEFb 抑制剂,对 CDK9/CyclinT1 的 IC50 为 6 nM。
-
Dinaciclib
一种有效的选择性 CDK 抑制剂,针对 CDK2、CDK5、CDK1 和 CDK9 的 IC50 分别为 1、1、3 和 4 nM。